Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of sex and heart size on cardiovascular adaptations to 2 years of endurance exercise training in sedentary middle-aged adults.

The Journal of physiology·2026
Same author

Sotatercept Safety and Efficacy in Intermediate- to Low-Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.

Chest·2026
Same author

Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.

American journal of respiratory and critical care medicine·2026
Same author

Sotatercept and Prostacyclin De-Escalation in Stable Pulmonary Arterial Hypertension: A Single-Centre Case Series.

American journal of respiratory and critical care medicine·2026
Same author

From Clinical Success to Physiologic Understanding: Disentangling Sotatercept's Effects in PAH.

Journal of the American College of Cardiology·2026
Same author

Recovery Experiences of Older Adults and Their Caregivers After Major Elective Noncardiac Surgery.

JAMA network open·2026
Same journal

Implantable cardioverter-defibrillator in cardiac sarcoidosis: A propensity-score matched analysis.

Current problems in cardiology·2026
Same journal

Arterial Stiffness in Heart Failure with Preserved Ejection Fraction: is this a new Predisposing Factor?

Current problems in cardiology·2026
Same journal

The future of cardiovascular training: Bridging global disparities and building a hybrid model for equity in care.

Current problems in cardiology·2026
Same journal

Disparities in healthcare access and treatment outcomes for patients with chronic limb-threatening ischemia.

Current problems in cardiology·2026
Same journal

Diagnostic and prognostic value of coronary computed tomography angiography and high-risk plaque assessment in acute coronary syndrome.

Current problems in cardiology·2026
Same journal

Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Current problems in cardiology·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Pulmonary arterial hypertension.

Vallerie V McLaughlin, Melinda Davis, William Cornwell

    Current Problems in Cardiology
    |November 1, 2011
    PubMed
    Summary
    This summary is machine-generated.

    Pulmonary hypertension (PH) is a complex condition classified into 5 groups. Advances in therapies like prostacyclins have improved patient quality of life and outlook for this progressive disease.

    More Related Videos

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
    08:34

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

    Published on: November 18, 2018

    The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
    07:29

    The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

    Published on: March 8, 2019

    Related Experiment Videos

    Last Updated: May 28, 2026

    Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
    08:08

    Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

    Published on: May 11, 2015

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
    08:34

    Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

    Published on: November 18, 2018

    The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
    07:29

    The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

    Published on: March 8, 2019

    Area of Science:

    • Cardiology
    • Pulmonology
    • Internal Medicine

    Background:

    • Pulmonary hypertension (PH) is a complex, multidisciplinary disorder with five distinct classification groups.
    • Pulmonary arterial hypertension (PAH) can be idiopathic, heritable, or associated with conditions like scleroderma or congenital heart disease.
    • PH commonly co-occurs with disorders increasing left heart filling pressures or causing hypoxemic lung disease, and can arise from chronic thromboembolic disease.

    Purpose of the Study:

    • To provide an overview of the classification, diagnosis, and recent therapeutic advancements in pulmonary hypertension.
    • To highlight the importance of a methodical evaluation for determining the etiology of PH.
    • To discuss the impact of novel therapies on patient outcomes.

    Main Methods:

    • Diagnostic evaluation typically begins with echocardiography to suggest PH.
    • Further investigations are crucial to identify potential associated causes of PH.
    • Right heart catheterization serves as the definitive diagnostic tool for PH.

    Main Results:

    • Recent decades have seen significant treatment advances for PH, transforming it from a devastating disease.
    • Therapies including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors have been developed.
    • These advancements have led to improved quality of life and prognosis for patients with progressive PH.

    Conclusions:

    • Pulmonary hypertension diagnosis requires a comprehensive evaluation, starting with non-invasive tests and culminating in right heart catheterization.
    • Modern pharmacotherapies have substantially improved the management and outlook for patients with various forms of pulmonary hypertension.
    • Continued research and multidisciplinary care are essential for addressing this complex cardiovascular and respiratory condition.